About Mercy BioAnalytics
Mercy BioAnalytics is a Healthcare company based in Boston (United States) founded in 2018 by Paul Blavin and Joseph Sedlak. Diagnostic test devices are manufactured for clinical applications. Mercy BioAnalytics has raised $127.28 million across 3 funding rounds from investors including LabCorp, Hologic and Bruker. The company has 18 employees. Its chief executive, as recorded, is Paul Blavin. Mercy BioAnalytics offers products and services including Mercy Halo Platform and Blood-based Tests. Its focus areas include Traditional Diagnostics. Its legal entity is Mercy BioAnalytics, Inc.
Company details
Mercy BioAnalytics was founded in 2018 and is based in Boston, United States. Diagnostic test devices are produced by the company within the biotechnology sector. Operations focus on developing and manufacturing these devices to support healthcare diagnostics. The firm is led by co-founders Paul Blavin as CEO and Joseph Sedlak as CSO. Activities are conducted through the domain mercybio.com, serving the medical industry in the region.
- Headquarters Boston, United States
- Employees 18
- Founders Paul Blavin, Joseph Sedlak
- SectorsHealthcare
- Website mercybio.com
- Social LinkedIn
- Legal Name Mercy Bioanalytics, Inc
- Total Equity Funding$127.28M (USD)
in 3 rounds
- Latest Funding Round$59M (USD), Series B
Sep 2025
- InvestorsLabCorp
& 14 more
- Employee Count18
Products & Services of Mercy BioAnalytics
Mercy BioAnalytics offers a comprehensive portfolio of products and services, including Mercy Halo Platform and Blood-based Tests.
The Mercy Halo platform is used for developing blood-based tests that identify early-stage cancer through extracellular vesicles
Blood-based tests are developed for detecting cancer at early stages using biomarker analysis on extracellular vesicles
Funding Insights of Mercy BioAnalytics
Mercy BioAnalytics has successfully raised a total of $127.28M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $59 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $127.28M
- Total Rounds 3
- Last Round Series B — $59M
- First Round $27.28M
(Jan 2021)
- Investors Count 15
All 3 funding rounds of Mercy BioAnalytics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2025 | $59M | Series B | – | Novalis LifeSciences, Sozo Ventures | |
| Apr 2023 | $41M | Series A | – | Novalis LifeSciences | |
| Jan 2021 | $27.28M | Series A | – | – | – |
15 investors in total: 15 institutional.
Investors in Mercy BioAnalytics
Mercy BioAnalytics has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include LabCorp, Hologic and Bruker.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment and advisory services are provided for life sciences. | 2017 | novalislifesciences.com | Portsmouth, USA | |
Tech & Life Sciences focused VC firm investing in early stage companies in the US & Europe | hatterasvp.com | Durham, United States | ||
Early-stage investments are targeted by iSelect Fund in key sectors. | iselectfund.com | St. Louis, United States | ||
Women-led angel network focused on tech companies | broadway-angels.com | San Francisco, United States | ||
Venture capital firm focused on multiple sectors | sozoventures.com | Redwood City, United States | ||
Venture capital firm creating funds for innovative companies in women's health and emerging markets. | portfolia.co | |||
Avestria Ventures is focused on funding women's health and life science ventures. | avestria.vc | San Francisco, United States | ||
| mindshiftcapital.com | ||||
Limited information is provided about SOZO Ventures' activities. | sozo.ventures | |||
Cancer Research UK is focused on funding cancer research. | cancer.org.uk | London, United Kingdom |
Investor details for Mercy BioAnalytics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Mercy BioAnalytics
17 people are tracked at Mercy BioAnalytics (7 in leadership, 10 in team); the tracked headcount is 18.
| Name | Role | Group |
|---|---|---|
Paul Blavin | Co-Founder & CEO | Leadership |
Joseph Sedlak | Co-Founder & CSO | Leadership |
Dawn Mattoon | Chief Executive Officer | Leadership |
Michael Smith | Senior Vice President Operations | Leadership |
Toumy G. | Chief Scientific Officer | Leadership |
Diane Marcou | Consulting CFO | Leadership |
Troy Hawkins | Senior Director, Computational Biology And Data Science | Leadership |
Michele Mara | Consultant - Financial Controller | Team |
MacKenzie King | Senior Research Associate | Team |
Ibukun Zabroski | Senior Scientist | Team |
Shawn Hunt | Laboratory Operations Manager | Team |
Bilal Hamzeh | Research Associate | Team |
Syrena Fernandes | Principal Scientist | Team |
Timothy Santos-Heiman | Research Associate | Team |
Sanchari Banerjee, Ph.D | Scientist II | Team |
Stephen Brinton | Bioinformatics Manager | Team |
Nadish Goyal | Manager, Development | Team |
Complete people profiles for Mercy BioAnalytics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Mercy BioAnalytics
3 dated milestones of Mercy BioAnalytics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Mercy BioAnalytics is founded.
- Funding First funding round of $27.3M.
- Funding Latest funding round, Series B, of $59.0M.
Web traffic of Mercy BioAnalytics
The website of Mercy BioAnalytics (mercybio.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▼ 36.4% vs previous month
Top companies in Traditional Diagnostics & Medical Devices
3 companies that operate in the same segment as Mercy BioAnalytics (Traditional Diagnostics & Medical Devices) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Materials management solutions are provided for healthcare organizations. | 1892 | Chicago, Illinois, United States | USD 29.13 M | USD 19.48 B | 95,424 | |
3D-printed orthopedic products are manufactured for medical applications. | 1941 | Kalamazoo, Michigan, United States | ||||
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | USD 5.1 B | 13,500 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mercy Bioanalytics
Complete news archive for Mercy BioAnalytics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mercy BioAnalytics
Mercy BioAnalytics was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Mercy BioAnalytics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Paul Blavin is the CEO of Mercy BioAnalytics, as recorded in our data. They have also founded this company.
Mercy BioAnalytics is a funded company, having raised a total of $127.28M across 3 funding rounds to date. The company's 1st funding round was a Series A of $27.28M, raised on Jan 2021.
Mercy BioAnalytics has 18 employees.
Mercy BioAnalytics was founded in 2018 and is based in Boston, United States. Diagnostic test devices are produced by the company within the biotechnology sector. Operations focus on developing and manufacturing these devices to support healthcare diagnostics. The firm is led by co-founders Paul Blavin as CEO and Joseph Sedlak as CSO. Activities are conducted through the domain mercybio.com, serving the medical industry in the region.
Mercy BioAnalytics offers Mercy Halo Platform and Blood-based Tests.
Mercy BioAnalytics has 15 investors. Key investors include LabCorp, Hologic, Bruker, Novalis LifeSciences, and SOZO Ventures.
Mercy BioAnalytics operates through Mercy Bioanalytics, Inc.